ACOTEC SCIEN.H. DL-00001

ACOTEC SCIEN.H. DL-00001

7W3 · F · Healthcare / Medical Devices

0.515EUR-0.03 (-5.50%)

Price History

Full chart

Market Stats

Previous Close0.545
Open0.515
Day Range0.515 – 0.515
52-Week Range0.60 – 1.59
Volume0
Market Cap203.70M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.02
Dividend Yield0.00%
Beta-0.04
50-Day Avg0.7052
200-Day Avg1.07

About

Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee arteries for the treatment of chronic limb-threatening ischemia with a vascular interventional approach. It also offers devices for vascular surgery, including AcoArt Iris & Jasmin; AcoArt Lily & Rosmarin; peripheral aspiration system; radiofrequency ablation system; peripheral support catheter; The PTA balloon; 2nd gen peripheral aspiration system; introducer sheath set; and the delivery catheter for aspiration catheter. In addition, it offers cardiology devices, including semi-compliant PTCA balloon; coronary CTO recanalization balloon; coronary CTO antegrade micro-catheter; coronary high-pressure balloon; cardiac valve balloon dilation catheter; AcoArt Camellia; and coronary micro-catheter. Further, the company provides nephrology devices, such as paclitaxel coated high-pressure balloon and AV scoring balloon; and neurology devices comprising intracranial PTA balloons and vertebral artery paclitaxel-coated balloon dilatation catheter, as well as trades in procedural medical devices. The company was founded in 2011 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of Boston Scientific Group plc.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMs. Jing Li
  • Employees955
  • HeadquartersBuilding No. 1, Beijing, China, Germany
  • Websitehttps://www.acotec.cn

Leadership

  • Ms. Jing LiExecutive Chairperson of the Board & CEO · b. 1973
  • Dr. Ulrich Reinhold SpeckChief Technology Officer · b. 1942
  • Mr. Chen LiJoint Company Secretary · b. 1991
  • Ms. Ching Yi LiJoint Company Secretary

Financials

Income Statement

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue303.81M395.55M473.85M533.99M644.63M
Growth (%)-+30.19%+19.80%+12.69%+20.72%
Cost of Revenue37.87M59.19M96.43M131.27M168.32M
Gross Profit265.94M336.35M377.42M402.72M476.31M
Gross Margin87.53%85.04%79.65%75.42%73.89%
Operating Expense292.60M336.42M355.86M365.82M371.15M
Operating Income-26.66M-65.00K21.56M36.90M105.16M
Operating Margin-8.78%-0.02%4.55%6.91%16.31%
EBITDA-91.17M70.54M112.48M185.21M
EBITDA Margin-23.05%14.89%21.06%28.73%
Net Income-79.08M70.14M14.49M52.28M119.18M
Net Income Margin-26.03%17.73%3.06%9.79%18.49%
R&D141.29M183.80M190.07M216.77M213.66M
R&D as % of Total Revenue46.50%46.47%40.11%40.60%33.15%
Interest Expense3.82M1.42M9.83M9.90M9.38M
Interest Expense % of Total Revenue1.26%0.36%2.08%1.85%1.46%

Balance Sheet

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.31B1.41B1.61B1.66B1.87B
Total Liabilities100.17M134.46M314.53M312.76M392.01M
Total Equity1.21B1.28B1.30B1.35B1.48B
Cash1.14B986.46M637.63M751.39M399.82M

Cash Flow

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-10.48M-68.75M-12.88M102.79M150.27M
Capital Expenditure21.24M46.70M79.66M97.48M81.15M
Free Cash Flow-31.72M-115.45M-92.54M5.31M69.12M
Dividends Paid323.08M----
FCF to OCF302.69%167.92%718.31%5.17%46.00%
Dividend Paid to FCF-1018.68%----

Key Statistics & Ratios

Market Cap203.70M
Enterprise Value-62.23M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.33
Price / Book0.09
EPS-0.02
Book Value0.5905
Revenue (TTM)625.00M
Gross Profit (TTM)448.99M
EBITDA140.43M
Profit Margin-8.04%
Operating Margin26.15%
Return on Equity-3.54%
Return on Assets3.98%
Shares Outstanding313.39M
Shares Float50.81M
Beta-0.04
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%